-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Beta Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLN-124 in Beta Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLN-124 in Beta Thalassaemia Drug Details: SLN-124 is under development for the...
-
Product Insights
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2023
Global Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2023’, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drugs In Development, 2023’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drugs In Development, 2023’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Occlusive Arterial Disease (OAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Occlusive Arterial Disease (OAD) - Drugs In Development, 2023’, provides an overview of the Occlusive Arterial Disease (OAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Occlusive Arterial Disease (OAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Artery Occlusive Disease (PAOD) - Drugs In Development, 2023’, provides an overview of the Peripheral Artery Occlusive Disease (PAOD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Artery Occlusive Disease (PAOD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Pulmonary Arterial Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pulmonary Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apabetalone in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apabetalone in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apabetalone in End-Stage Kidney Disease (End-Stage...